Gilles Salles's guest appearances

Gilles Salles

EHA Hematology Podcast

Oncology Data Advisor

Oncology Today with Dr Neil Love

Corey Langer

Michael Mauro

Ian Krop

Sara Tolaney

Matthew Davids

Bradley Monk

Ezra Cohen

Tom Lynch

Eric Klein

John Heymach

Leora Horn

Jeffrey Bradley

Benjamin Levy

Kathleen Moore

Steven Horwitz

OwlTail

Dr Gilles Salles from Memorial Sloan Kettering Cancer Center in New York City discusses recent data from clinical trials evaluating targeted therapies for diffuse large B-cell lymphoma. CME information and select publications here.

Dr Gilles Salles from Memorial Sloan Kettering Cancer Center in New York City discusses recent data from clinical trials evaluating targeted therapies for diffuse large B-cell lymphoma. CME information and select publications <a href="http://www.researchtopractice.com/OncologyTodayDLBCL22" rel="nofollow" target="_blank">here</a>.

Advances in Diffuse Large B-Cell Lymphoma with Dr Gilles Salles

Dr Gilles Salles from Memorial Sloan Kettering Cancer Center in New York discusses recently published and emerging research on the treatment of diffuse large B-cell lymphoma. CME information and select publications here.

Dr Gilles Salles from Memorial Sloan Kettering Cancer Center in New York discusses recently published and emerging research on the treatment of diffuse large B-cell lymphoma. CME information and select publications <a href="http://www.researchtopractice.com/OncologyTodayDLBCL21" rel="nofollow" target="_blank">here</a>.

Novel and Emerging Strategies for Diffuse Large B-Cell Lymphoma with Dr Gilles Salles

To claim CME credit for this podcast, visit https://i3health.com/oda-mclAn aggressive form of B-cell non-Hodgkin lymphoma, mantle cell lymphoma (MCL) is a challenging disease to treat, with a median overall survival of 6 to 7 years. Even in patients who achieve a complete response, recurrence and relapse are still frequent. In this episode of Oncology Data Advisor, Gilles Salles, MD, PhD, Chief of the Lymphoma Service at Memorial Sloan Kettering Cancer Center, joins i3 Health for a discussion that covers the efficacy of newly developed Bruton tyrosine kinase (BTK) inhibitor and chimeric antigen receptor (CAR) T-cell therapies, the management of adverse events associated with these treatments, updates on ongoing research, and advice for clinicians as they seek to optimize outcomes for patients with MCL.

To claim CME credit for this podcast, visit <a href="https://i3health.com/oda-mcl" rel="nofollow" target="_blank">https://i3health.com/oda-mcl</a> An aggressive form of B-cell non-Hodgkin lymphoma, mantle cell lymphoma (MCL) is a challenging disease to treat, with a median overall survival of 6 to 7 years. Even in patients who achieve a complete response, recurrence and relapse are still frequent. In this episode of Oncology Data Advisor, Gilles Salles, MD, PhD, Chief of the Lymphoma Service at Memorial Sloan Kettering Cancer Center, joins i3 Health for a discussion that covers the efficacy of newly developed Bruton tyrosine kinase (BTK) inhibitor and chimeric antigen receptor (CAR) T-cell therapies, the management of adverse events associated with these treatments, updates on ongoing research, and advice for clinicians as they seek to optimize outcomes for patients with MCL.

Novel Treatment Options in Mantle Cell Lymphoma With Gilles Salles, MD, PhD